Document:

Non-Exclusive Sales Representative and Services Agreement dated Nov. 12, 2002

 Exhibit 10.15 
  
 HEMOSENSE, INC. 
  
 NON-EXCLUSIVE SALES REPRESENTATIVE AND SERVICES AGREEMENT 
  
 This Non-Exclusive Sales Representative and Services Agreement (this “Agreement”) takes effect November 12, 2002 (“Effective Date”), between
HemoSense, Inc. (“HemoSense”), a Delaware corporation with principal offices at 600 Valley Way, Milpitas, CA 95035, USA, and Innovative Medical Product Consultants, GmbH (“Representative”), a business organized and existing under
the laws of Germany with principle offices at Max-Planck-Strasse 22, 50858 Cologne, Germany. 
  
 The parties agree as follows: 
  
 THE AGREEMENT 
  

	1.	DEFINITIONS 

  
 All defined terms appear in Schedule A. 
  

	2.	APPOINTMENT AND AUTHORITY OF I-MED PRO 

  

	 	2.1	Sales Representative Appointment. Subject to the terms and conditions of this Agreement, including all Schedules and bound by the definitions in Schedule A, HemoSense hereby
appoints I-Med Pro as HemoSense’s non-exclusive sales representative for the Products listed in Schedule B, only in the Territory, and I-Med Pro hereby accepts this appointment. I-Med Pro’s sole authority is to solicit and receive Product
orders in the Territory, assist HemoSense in filling Product orders that HemoSense accepts (including, but not limited to, those that I-Med Pro solicits), and provide support services to Product customers, all in accordance with the terms of this
Agreement. I-Med Pro has no power or authority, expressed or implied, to make any commitment or incur any obligations on HemoSense’s behalf. 

  

	 	2.2	Reserved Rights. HemoSense may: 

  

	 	(A)	Solicit orders directly from and sell directly to any customer and all distributors within the Territory; and 

  

	 	(B)	Appoint other distributors in the Territory to solicit and receive Product orders from customers, assist HemoSense in filling Product orders (including, but not limited to, those
that I-Med Pro solicits), and provide support services to customers. 

  

	 	2.3	Territorial Limitation. I-Med Pro shall neither advertise the Products outside the Territory nor solicit purchase orders from outside the Territory without HemoSense’s
prior written consent. I-Med Pro shall promptly submit to HemoSense, for HemoSense’s attention and handling, the originals of all inquiries received by I-Med Pro from potential customers outside Territory. 

  

	 	2.4	Independent Contractors. The relationship that this Agreement establishes between HemoSense and I-Med Pro is that of independent contractors, and nothing contained in this
Agreement may be construed to give either party the power to direct and control the day-to-day activities of the other, or to constitute the parties as partners, joint venturers, co-owners or otherwise as participants in a joint undertaking. I-Med
Pro is solely responsible for, and shall indemnify and hold HemoSense free and harmless from, any and all claims, damages or lawsuits (including HemoSense’s attorneys’ fees) arising out of the acts of I-Med Pro, its employees or its
agents. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

	3.	SALE OF THE PRODUCTS 

  

	 	3.1	Prices and Terms of Sale. HemoSense shall provide I-Med Pro with copies of its current price lists, its delivery schedules, and its standard terms and conditions of sale, as
established from time to time. I-Med Pro may quote to customers only those authorized prices, delivery schedules, and other terms and conditions of sale. HemoSense may alter at will the prices, delivery schedules, and terms and conditions, provided
only that it gives prior written notice to I-Med Pro of any changes. Each purchase order shall be governed by HemoSense’s prices, delivery schedules, and other terms and conditions of sale in effect at the time the purchase order is accepted by
HemoSense, and all quotations by I-Med Pro shall contain a statement to that effect. 

  

	 	3.2	Quotations. I-Med Pro shall promptly furnish to HemoSense copies of all quotations submitted by I-Med Pro to customers. Each quotation shall accurately reflect the terms of
this Agreement. 

  

	 	3.3	Purchase orders. All purchase orders for the Products shall be in writing, and the originals shall be submitted to HemoSense. 

  

	 	3.4	Acceptance. All purchase orders obtained by I-Med Pro are accepted on behalf of HemoSense. 

  

	4.	ASSISTANCE WITH ORDER FULLFILMENT 

  

	 	4.1	Receiving Services. To assist HemoSense in fulfilling purchase orders (“Accepted Territory Orders”), I-Med Pro shall provide HemoSense receiving services by
accepting the delivery, on HemoSense’s behalf, of all Products that HemoSense intends to deliver within the Territory. Upon receipt of any such Products, I-Med Pro shall promptly inspect the Products and notify HemoSense of its receipt of the
Products and of any defects discovered. 

  

	 	4.2	Warehousing Services. 

  

	 	(A)	I-Med Pro shall provide HemoSense with storage and warehousing services with respect to Products that HemoSense intends to deliver to customers within the Territory, including those
Products that I-Med Pro receives under Section 4.1. All Products that I-Med Pro houses for HemoSense must be in a secure storage location segregated from I-Med Pro or other I-Med Pro customer materials. 

  

	 	(B)	At least once per calendar quarter, I-Med Pro shall perform a physical inventory audit of Products stored on HemoSense’s behalf (“I-Med Pro Inventory”). In addition,
HemoSense reserves the right to perform its own physical inventory audit at I-Med Pros’ facilities during normal business hours upon 5 business days prior written notice. 

  

	 	4.3	Delivery Services. HemoSense may request I-Med Pro’s assistance in filling any Accepted Territory Order by [delivering a copy of the order (or information concerning the
order)] to I-Med Pro. In such case, I-Med Pro shall deliver Product from the I-Med Pro Inventory to customer under an Accepted Territory Order as HemoSense’s standard terms and conditions of sale require. 

  

	 	4.4	Invoice / Collection Services. 

  

	 	(A)	Concurrently with each Product delivery under Section 4.3, I-Med Pro shall render an invoice for the delivered Product directly to the customer. Such invoices shall be (i) rendered
on HemoSense’s behalf (but direct the customer to render payment to I-Med Pro), (ii) consistent with HemoSense’s standard terms and conditions for sale, and (iii) in a form that HemoSense approves of in advance. 

 

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -2- 

	 	(B)	I-Med Pro shall perform collection services with respect to all invoices that I-Med Pro renders on HemoSense’s behalf, using best effort to collect all invoiced amounts. Upon
receipt of payments from customer, I-Med Pro shall promptly pay all such amounts to HemoSense. All collected amounts belong exclusively to HemoSense. I-Med Pro has no right to withhold any collected amounts from HemoSense. 

 

	 	4.5	Reporting. I-Med Pro shall promptly provide HemoSense with quarterly reports that list: (i) the levels of I-Med Pro Inventory for each Product; (ii) Product deliveries from
the I-Med Pro Inventory; (iii) amounts I-Med Pro has collected from customers; (iv) amounts I-Med Pro has paid to HemoSense; and (v) any uncollected amounts. 

  

	 	4.6	Risk of Loss / Title. HemoSense retains all title to the I-Med Pro Inventory and retains all risk of loss, unless I-Med Pro has been found negligent in the storage of
equipment, loss due to theft or an act of God, until delivery of the I-Med Pro Inventory from I-Med Pro to the customer, at which time title shall pass directly from HemoSense to the customer pursuant to the terms of HemoSense’s standard terms
and conditions of sale. I-Med Pro is required to maintain insurance against the risk of loss described above 

  

	5.	SUPPORT SERVICES 

  

	 	5.1	Installation. To the extent required, I-Med Pro shall be responsible for the installation of the Product for end-user customers in the Territory. 

  

	 	5.2	Service and Support. I-Med Pro shall provide support and maintenance to end-user customers of the Product in the Territory. I-Med Pro shall maintain knowledgeable sales,
marketing, and support personnel to provide instructions to end-user customers in the use of the Product. Such sales, marketing, and support personnel shall (i) attend hands-on training sessions relating to the Product as HemoSense reasonably
requests and (ii) observe the use of Product in application to improve the clinical knowledge of the Product. I-Med Pro is fully responsible for any and all technical support of end-user customers within the Territory, and shall diligently assist
such end-user customers’ personnel in using Product (iii) I-Med Pro shall provide a technical service line in house that is answered 8:00 am to 5:00 pm Monday through Friday. 

  

	 	5.3	Telephone Marketing and Technical Support. If necessary, HemoSense shall provide a reasonable level of telephone marketing and technical support to employees of I-Med Pro who
have been trained by HemoSense during its normal business hours to answer I-Med Pro’s questions related to Product. 

  

	 	5.4	Technical Support. I-Med Pro will provide information to HemoSense on issues related to product performance or misuse. This will include (i) distribution records and system
documentation of all and any events, (ii) based on the nature of the event report back to HemoSense within a 48 hour time frame, (iii) from time to time allow audits of the I-Med Pro facility for compliance to a quality system.

  

	6.	COMPENSATION AND EXPENSES 

  

	 	6.1	Compensation. 

  

	 	(A)	 For services provided under this Agreement for Step one Schedule C “I-Med Pro the Importer and European Representative of HemoSense”, HemoSense hereby
grants to I-Med Pro a one-time purchase of [45,000] shares (the “Warrants”, per 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -3- 

	 	 
Schedule D) of HemoSense’s [$.01] par value common stock (the “Common Stock”) (as adjusted from time to time upon the occurrence of any
subdivision, stock split, combination or change of Common Stock into different numbers of shares of the same or any other class or classes of shares) at an exercise price of [$0.20] per share. Subject to I-Med Pro’s performance of its
obligations under this Agreement, the options shall vest upon completion of certain milestones, as follows: 

  
 (1) [25% at Effective Date] 
  
 (2) [25% upon completion of the first third of this Agreement’s initial term] 
  
 (3) [25% upon completion of the second third of this Agreement’s initial term] 
  
 (4) [25% upon completion of this Agreement’s initial term.]

  

	 	(B)	For services provided under this Agreement for the addition of Step two of Schedule C “I-Med Pro the Account manager for Subs” and “I-Med Pro is the Sub in Defined
Accounts”, HemoSense hereby grants to I-Med Pro a one-time purchase of [20,000] shares (the “Warrants” per Schedule D) of HemoSense’s [$.01] par value common stock (the “Common Stock”) (as adjusted from time to time
upon the occurrence of any subdivision, stock split, combination or change of Common Stock into different numbers of shares of the same or any other class or classes of shares) at an exercise price of [$0.20] per share. Subject to I-Med Pro’s
performance of its obligations under this Agreement, the options shall vest upon completion of certain milestones, as follows: 

  
 (1) [50% at Effective Date] 
  
 (2) [25% based on providing to the Subs [***] meters and [***] strips] 
  
 (3) 25% upon completion of the initial term 
  
 If HemoSense terminates this Agreement for its convenience under Section 11.2(B), 50% of any unvested shares that I-Med Pro
purchased under this Agreement shall immediately vest. The grant, vesting and other terms of the warrant grant under this Agreement shall accord with the Warrant to Purchase Common Shares of HemoSense (attached and incorporated into this Agreement
as Schedule D). If there is any conflict between the terms of this Section 6.1 and the terms of Schedule D, the terms of Schedule D shall control. 
  

	 	6.2	Expenses. I-Med Pro may invoice HemoSense for customary, reasonable and necessary out-of-pocket expenses that I-Med Pro incurs as a direct result of performing the Services
under this Agreement (“Actual Expenses”), [with a [***]% mark-up]. These expenses are based on a budget submitted and approved by HemoSense. Any items not approved by this budget (see Schedule E) must be pre-approved in writing by
HemoSense for amounts over $5,000 USD] With each invoice, I-Med Pro shall provide HemoSense with a written description that reasonably details each Actual Expense that is the subject of I-Med Pro’s invoice. I-Med Pro must provide a budget
estimate of expenses and submit them monthly. 

  
 6.2.1 As a retainer for such expenses, the Company shall maintain an amount in ImedPro’s accounts equivalent to the estimated 3 months forward expenses per budget attached in Schedule E and VAT on product to be imported. Appendix A is
a current estimate of expense to be incurred under this Agreement. 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -4- 

 Schedule E — is a current estimate of Actual Expenses to be reimbursed as provided by I-Med Pro.

  
 6.2.1 Payment. Payments under this Agreement shall be in
Euros (except as set forth under Section 6.1), and are subject to all applicable governmental regulations and rulings, including the withholding of any taxes required by law. 
  

	 	6.3	Time of Payment. The amount due under a given invoice is due and payable net thirty (30) days after receipt of the invoice from I-Med Pro to the third party

  

	7.	AUDITS 

  
 HemoSense reserves the right to authorize a HemoSense I-Med Pro, at HemoSense’s expense, to audit I-Med Pro records relating to the Product,
including, without limitation, any expense, sales and inventory records and any records required to be kept pursuant to this Agreement. Upon prior written notice, I-Med Pro shall provide reasonable access to such records during normal business hours
at Distributor’s business locations. Distributor shall maintain all such records by location for a minimum of three (3) years 
  

	8.	PRODUCT WARRANTY AND PRODUCT AVAILABILITY 

  

	 	8.1	Product Warranty. Any warranty for the Products runs directly from HemoSense to the customer, and pursuant to the warranty the customer shall return any allegedly defective
Products to HemoSense via it’s agent I-Med Pro. I-Med Pro has the authority to authorize returns at their discretion and under parameters established by HemoSense. 

  

	 	8.2	Disclaimer. HEMOSENSE MAKES NO WARRANTIES OR CONDITIONS TO 1- MED PRO, EXPRESS, STATUTORY, IMPLIED, OR OTHERWISE, AND HEMOSENSE SPECIFICALLY DISCLAIMS THE IMPLIED WARRANTIES
AND CONDITIONS OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 

  

	 	8.3	Product Availability. Under no circumstances is HemoSense liable to I-Med Pro or any other party for its failure to fill accepted purchase orders, or for its delay in filling
accepted purchase orders, when such failure or delay is due to any cause beyond HemoSense’s reasonable control. 

  

	9.	OTHER I-MED PRO OBLIGATIONS 

  

	 	9.1	Promotion of the Products. In no event may I-Med Pro make any representation, guarantee or warranty concerning the Products except as expressly authorized in writing by
HemoSense. I-Med Pro shall indemnify, defend, and hold harmless HemoSense, its directors, officers, agents, and affiliates against any liability, loss, costs, or damages arising out of or related to I-Med Pro’s warranties or representations of
the Products other than those warranties expressly authorized in writing by HemoSense. 

  

	 	9.2	Advising of Changes. Both parties shall have the responsibility to promptly advise each other of: 

  

	 	(A)	Any changes in either parties status, organization, personnel, and similar matters; 

  

	 	(B)	Any changes in the key personnel, organization, and status of customers in the Territory; and 

  

	 	9.3	Facilities. I-Med Pro shall provide itself with, and be solely responsible for the facilities, employees, and business organization, and the permits, licenses, and other
forms of clearance to do business in the territory, as it deems necessary for the conduct of its business operations in accordance with this Agreement. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -5- 

	 	9.4	Expense of Doing Business. Except as provided in Section 6.1, I-Med Pro shall bear the entire cost and expense of conducting its business in accordance with the terms of this
Agreement. 

  

	 	9.5	Books and Records. I-Med Pro shall maintain and make available to HemoSense accurate books, records, and accounts relating to the business of I-Med Pro with respect to the
Products and the Actual Expenses for which reimbursement is sought under this Agreement. I-Med Pro shall also maintain a record of any customer complaints regarding either the Products or HemoSense and immediately forward to HemoSense the
information regarding those complaints. 

  

	 	9.6	Proprietary Markings. I-Med Pro shall not remove, alter or destroy any proprietary, trademark, patent or copyright markings placed upon or contained within the Products.
I-Med Pro shall insert and maintain such proprietary, trademark, patent or copyright markings within any Product-related materials or documentation. HemoSense and its licensors retain all right, title and interest in the Products, and all trademark
rights, copyrights, patents, mask work rights and other intellectual property rights therein throughout the world. 

  

	10.	PROMOTIONAL MATERIALS 

  
 HemoSense shall furnish I-Med Pro with marketing and technical information concerning the Products as well as reasonable quantities of brochures,
instructional material, advertising literature, and other Product data. Any brochures, material, or literature that HemoSense provides to I-Med Pro under this Agreement, are HemoSense’s property, and shall be returned upon HemoSense’s
request. 
  

	11.	TERM AND TERMINATION 

  

	 	11.1	Term. 

  

	 	(A)	This Agreement’s initial term begins on the Effective Date and ends after one year, unless terminated earlier under this Section 11. For providing the services described in
Step 1 and Step 2 of Exhibit C the parties may renew this Agreement for successive one-year terms by written agreement 90 days before the anniversary date on which the Agreement would otherwise expire. 

  

	 	11.2	Termination. 

  

	 	(A)	Termination for Cause. If either party defaults in the performance of any provision of this Agreement, then the non-defaulting party may give 30-day written notice of termination to
the defaulting party. If the default is not cured within that 30-day period, the Agreement terminates at the end of the notice period. 

  

	 	(B)	Termination for Convenience. Either party may terminate this Agreement for any or no reason upon 90 days prior written notice to the other party. 

  

	 	(C)	Additional Termination Provisions. Either party may terminate this Agreement immediately upon written notice: 

  

	 	(1)	If either party: 

  

	 	(a)	Becomes insolvent or files or has filed against it a petition in bankruptcy (which is not dismissed within thirty (30) days after it is filed); or 

  

	 	(b)	Makes an assignment for the benefit of creditors; or (iii) dissolves or ceases to do business in the ordinary course; or 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -6- 

	 	(2)	Upon or after any government of the Territory’s enacting any law, decree, or regulation that would impair or restrict: 

  

	 	(a)	Either party right to terminate or elect not to renew this Agreement as provided under this Agreement; 

  

	 	(b)	Either party right, title or interest in the Products or the intellectual property rights in the Products; or 

  

	 	(c)	Either party right to receive payments for the Products. 

  

	 	11.3	Rights Upon Termination. 

  

	 	(A)	Return of Materials. All Product inventory, trademarks, trade names, patents, copyrights, designs, drawings, formulas or other data, financial information, business plans,
photographs, samples or demonstration units, literature, and sales aids of every kind remain HemoSense’s property. Within 30 days after the termination of this Agreement, I-Med Pro shall prepare all such items in its possession for shipment, as
HemoSense may direct, at HemoSense’s expense. I-Med Pro shall not make or retain any copies of any confidential items or information that may have been entrusted to it. Effective upon the termination of this Agreement, I-Med Pro shall cease to
use HemoSense’s Trademarks. 

  

	 	(B)	Sales I-Med Pro Claims. Upon termination or expiration of this Agreement, all claims of I-Med Pro against HemoSense including without limitation those pertaining to sales
compensation are hereby waived unless made in writing to HemoSense by I-Med Pro within 90 days of the date when the compensation would have been payable. 

  

	 	(C)	Survival. The provisions of Sections 4.6, 7, 9.5, 9.6, 11.3, 12, 0, 13.l(E) and 14 survive the termination or expiration of this Agreement. All other rights and obligations
of the parties cease upon this Agreement’s termination or expiration. 

  

	 	(D)	Arbitration. Both parties agree to use their best efforts in a good faith attempt to settle as promptly as possible any and all disputes arising from this Agreement or a
transaction conducted pursuant to this Agreement; but failing an amicable settlement, the parties agree that: 

  

	 	(1)	Any controversy or claim arising out of or relating to this Agreement shall be submitted to arbitration in accordance with the Rules of Conciliation and Arbitration then obtaining
of the International Chamber of Commerce before one arbitrator chosen in accordance with said rules 

  

	 	(2)	Such arbitration shall be held in English language in San Francisco, California 

  

	 	(3)	The award in such arbitration shall be final, binding and conclusive, and 

  

	 	(4)	Judgment on any award of any such arbitrator may be entered in any court having jurisdiction thereof. 

  

	12.	LIMITATION ON LIABILITY 

  
 HEMOSENSE IS LIABLE TO I-MED-PRO OR ANY THIRD PARTY FOR COSTS OF PROCUREMENT OF SUBSTITUTE GOODS, OR ANY OTHER SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR
INDIRECT DAMAGES, HOWEVER CAUSED, AND WHETHER BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE), PRODUCTS LIABILITY OR ANY OTHER THEORY OF LIABILITY, REGARDLESS OF WHETHER HEMOSENSE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES CONFIDENTIALITY

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -7- 

 I-Med Pro acknowledges that by reason of its relationship to HemoSense under this Agreement, it will have
access to certain information and materials concerning HemoSense’s business, plans, customers, technology, and products that are confidential and of substantial value to HemoSense, which value would be impaired if such information were
disclosed to third parties, I-Med Pro shall not use in any way for its own account or the account of any third party other than to fulfill its express obligations under this Agreement, nor disclose to any third party, any such confidential
information revealed to it by HemoSense. I-Med Pro shall take every reasonable precaution to protect the confidentiality of such information. Upon I-Med Pro’s request, HemoSense shall advise whether or not it considers any particular
information or materials to be confidential. All marketing and financial information, business plans, and technical information disclosed to I-Med Pro by HemoSense whether orally or in writing, and all customer lists, are to be considered
HemoSense’s confidential information. I-Med Pro shall not publish any technical description of the Products beyond the description that HemoSense publishes. Upon this Agreement’s termination or expiration, I-Med Pro shall not use or
disclosure any HemoSense confidential information, and I-Med Pro shall not manufacture or have manufactured any devices, components or assemblies utilizing HemoSense’s confidential information. 
  

	13.	TRADEMARKS AND TRADE NAMES 

  

	 	13.1	Use. During the term of this Agreement, I-Med Pro may indicate to the public that it is an authorized I-Med Pro of the Products and to advertise those Products under
HemoSense’s Trademarks, subject to the following: 

  

	 	(A)	Upon 30 days prior written notice to I-Med Pro, HemoSense may substitute alternative marks for any or all of HemoSense’s Trademarks; 

  

	 	(B)	If I-Med Pro intends to use representations of HemoSense’s Trademarks, I-Med Pro shall: 

  

	 	(1)	First submit those representations to HemoSense for approval of design, color, and other details (which shall not be unreasonably withheld); or 

  

	 	(2)	Use exact copies of those that HemoSense uses; 

  

	 	(C)	I-Med Pro shall fully comply with all reasonable guidelines, if any, that HemoSense communicates concerning the use of HemoSense’s Trademarks; 

  

	 	(D)	I-Med Pro shall not alter or remove any of HemoSense’s Trademarks affixed to the Products by HemoSense; and 

  

	 	(E)	At no time during or after the term of this Agreement shall I-Med Pro: 

  

	 	(1)	Challenge or assist others in challenging HemoSense’s Trademarks (except to the extent expressly prohibited by applicable law) or their registration; or

  

	 	(2)	Attempt to register any trademarks, marks or trade names confusingly similar to HemoSense’s Trademarks. 

  

	 	13.2	No Implied License. Except as set forth in this Section 13, nothing contained in this Agreement grants or may be deemed to grant to I-Med Pro any right, title or interest in
or to HemoSense’s Trademarks. All uses of HemoSense’s Trademarks, and the associated goodwill, inure solely to HemoSense. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -8- 

	14.	GENERAL PROVISIONS 

  

	 	14.1	Governing Law; Jurisdiction. This Agreement is to be governed by and construed under the laws of the State of California without reference to conflicts-of-laws principles.
The parties hereby expressly consent to the exclusive jurisdiction and venue of the federal and state courts within the State of California to adjudicate any dispute arising out of or related to this Agreement. 

  

	 	14.2	Notices. Any notice required or permitted to be given under this Agreement shall be delivered: (i) by hand; (ii) by registered or certified mail, postage prepaid, return
receipt requested, to the address of the other party first set forth above, or to such other address as a party may designate by written notice in accordance with this Section 14.2; or (iii) by overnight courier. Notice so given will be considered
effective when received, or if not received by reason of fault of addressee, when delivered. 

  

	 	14.3	Force Majeure. Nonperformance of either party is excused to the extent that performance is rendered impossible by strike, fire, flood, governmental acts, delay in component
supply, equipment failure, orders or restrictions, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence of the non-performing party. 

  

	 	14.4	Non-Assignability and Binding Effect. A mutually agreed consideration for HemoSense’s entering into this Agreement is the reputation, business standing, and goodwill
already honored and enjoyed by I-Med Pro under its present ownership, and, accordingly, I-Med Pro’s rights and obligations under this Agreement shall not be transferred or assigned directly, indirectly or by a change in control without
HemoSense’s prior written consent. Subject to the foregoing, this Agreement is binding upon and inures to the benefit of the parties hereto, their successors and permitted assigns. 

  

	 	14.5	Modification. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, is effective unless in writing signed by the party to be
charged, and the waiver of any breach or default does not constitute a waiver of any other right under this Agreement or any subsequent breach or default. 

  

	 	14.6	Severability. The parties intend every provision of this Agreement to be severable. If a court of competent jurisdiction determines that any provision is illegal or invalid
for any reason, the illegality or invalidity will not affect the validity of the remainder of this Agreement, and the parties will in good faith modify or substitute the illegal or invalid provision consistent with the parties’ original intent.

  

	 	14.7	Counterparts. This Agreement may be executed in two or more counterparts, each of which is considered an original. 

  

	 	14.8	Entire Agreement. This Agreement sets forth the parties’ entire agreement and understanding – and merges all prior discussion between them – relating to the
subject matter of the Agreement. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, is effective unless in writing signed by the party to be charged. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -9- 

							
	Signed:	 	 	 	 
		
	HEMOSENSE, INC.	 	 INNOVATIVE MEDICAL PRODUCT
 CONSULTANTS,
GMBH

				
	Signature:	 	 /s/ J. D. Merselis

	 	Signature:	 	 /s/ Gregory M. Ayers

	Name:	 	J. D. MERSELIS	 	Name:	 	Gregory M. Ayers
	Title:	 	PRES. & CEO	 	Title:	 	[ILLEGIBLE]
			
	 	 	 	 	Pending Schedule D being agreeable to both partners.

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -10- 

 SCHEDULE A 
  

	1.	“Accepted Territory Order” has the meaning set forth in Section 3.3. 

  

	2.	“HemoSense’s Trademarks” means the trademarks, marks, and trade names that HemoSense owns or may adopt from time to time. 

  

	3.	“Products” means the products listed in Exhibit A (attached and incorporated into this Agreement). HemoSense may amend Exhibit A in its sole discretion upon 30 days prior
written notice to I-Med Pro. 

  

	4.	“I-Med Pro Inventory” means Products that I-Med Pro houses for HemoSense under Section 4.2 of this Agreement. 

  

	5.	‘Territory”. Means the Federal Republic of Germany 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 SCHEDULE B 
  
 PRODUCTS 
  
 I-Med Pro may solicit purchase orders only for the following Products: 
  
 INRatio Self Test System 
 INRatio Professional System 
 INRatio Strips 
 INRatio Meters 
 INRatio Printer 

INRatio Power Supply 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -12- 

 SCHEDULE C 
 Defined Steps and Responsibilities for I-Med Pro 
  
 Step 1: I-Med Pro The Importer and European Representative of HemoSense, Inc. 
  
 A) Importing of Goods 
 B) VAT Handling 
 C) Stock Products 
 D) Warehousing with a
total space of 100 square feet 
 E) Ship products to subs 
 F) Tracking Shipments 
 G) Invoicing to subs 
 H) Transfer sub payments to HemoSense, Inc. Complaint Handling 
 I) Online Telephone Support 
 J) Reporting to HemoSense, Inc. 
  
 Step 2: I-Med Pro the Account Manager for Subs 
  
 A) Managing the Accounts, regular calls at Inamed and MT Basa 
  
 B) Contract between Inamed and HemoSense 
  

	 	a.	Whereby I-Med Pro Staff support and develop the accounts Identified and converted by MTBasa 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -13- 

 SCHEDULE D 
  
 Warrant to Purchase Common Shares of HemoSense, Inc. 
  
 Assumed to be of same terms as prior Warrant issued to I-Med Pro 
  

	
	 /s/ Gregory M. Ayers

	
	11/12/2002
	
	 /s/ J. D. Merselis

	
	 11/12/2002

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -14- 

 SCHEDULE E 
  
 Budget Submitted by I-Med Pro 
  
 Step 1: I-Med Pro The Importer and European Representative of HemoSense, Inc. 
  
 Annual Expense Estimate: [***] Euro 
  
 Step 2: I-Med Pro the Account Manager for Subs 
  
 Annual Expense Estimate: [***] Euro 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

 -15-Distribution Agreement dated April 1, 2003

 Exhibit 10.16 
  
 DISTRIBUTION AGREEMENT 
  
 between 
  
 HemoSense, Inc 
 600 Valley Way 
 Milpitas, CA 95035 USA 
  
 represented by Jim Merselis 
 CEO HemoSense Inc. 
  
 - hereinafter referred to as “HemoSense” - 
  
 and 
  
 Inamed KG 
 Heinz
Galinski Str.l 
 13347 Berlin 
 represented by Ina Battke 
 Managing Shareholder of Inamed KG 
  
 - hereinafter referred to as “Inamed” - 
  
 Preamble 
  
 The two parties have agreed to interpret this agreement in a positive sense for the benefit of both of them and to cooperate in a spirit of partnership 
  
 HemoSense wishes to market anticoagulants in Europea and abroad and to continuously increase
its market presence. For this purpose HemoSense plans to put distributors in place in the various regional and national markets who will not only market the products, but also be technically and professionally qualified to train people to use the
product and its technical applications. One of these local distributors will be Inamed. The products will be imported to Germany by HemoSense or by a third party commissioned by HemoSense. Said third party will also be responsible - on the basis of
a separate agreement with HemoSense - for maintaining centralized storage facilities for the products, delivering the products to the distributors as and when ordered by them, and processing the financial side of the individual transactions.
However, it is not the responsibility of the third party to deliver or market the products to end users. 
  
 § 1 Subject Matter of the Agreement 
  

	 	(1)	Effective 01.04.2003 HemoSense assigns to Inamed the right to distribute the Contractual Products defined in § 2 in the Contractual Territory defined in § 3.

  

	 	(2)	Inamed shall purchase and sell the Products in its own name and for its own account. 

  

	 	(3)	Inamed shall act as a free and independent contractor. 

  

	 	(4)	Unless otherwise agreed in writing in a particular case, Inamed shall have no right to represent HemoSense for the purpose of entering into legal transactions, nor to assume
obligations on HemoSense’s behalf. Inamed shall refrain from doing anything that may give third parties the impression that they are authorized to do so. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 1 of 12

	 	(5)	HemoSense shall be entitled to appoint a representative to represent its marketing interests. At the time of entry into this agreement, this function is being performed by the firm
of I•Med•Pro GmbH, Max-Planck-Str. 22, 50858 Cologne. HemoSense reserve the right to appoint the representative themselves and, if need be, to replace the representative and dismiss it without replacement, had to limit or cancel its
responsibilities and proxy and the nature and scope thereof at any time by written or electronic communication to Inamed. Details of the powers of representation of I•Med•Pro GmbH are set forth in Exhibit 3. They have no powers
other than those set forth therein. 

  
 § 2
Products  
  

	 	(1)	Contractual Products are the products listed in Attachment 1. 

  

	 	(2)	Should HemoSense decide after conclusion of this agreement to add further products to its sales program, they may be offered to Inamed for them to distribute, but subject to newly
defined conditions. If the product newly added to the sales program is the followup product of a product withdrawn from the sales program and if it is similar in terms of price and function to the same, the newly-added products shall automatically
become a Contractual Product, with the result that the terms and conditions hereof shall automatically apply. 

  

	 	(3)	Within its general distribution policy is entitled to change single Contractual Products or withdraw single products from the Contractual Products; the total supply of Contractual
Products, however, shall not be changed considerably hereby; Inamed will be given at least 2 months prior written notice of any such changes. If, when Inamed receive a written notice from HemoSense, they have already concluded a purchase contract
with a client for the product(s) concerned or otherwise given some relevant binding declaration, and if Inamed inform HemoSense accordingly immediately after receiving written notice, then HemoSense shall be obliged to sell and deliver to Inamed the
number of products concerned. 

  
 § 3
Contractual Territory 
  

	 	(1)	The Contractual Territory is the territory described in Attachment 2 (the Länder). 

  

	 	(2)	The parties are in agreement that the Contractual Territory will be Inamed’s main sales territory, it being understood that this shall not constitute any geographical
limitation on Inamed’s distribution rights. 

  

	 	(3)	Inamed distribution rights are non-exclusive. HemoSense shall have the right to distribute the Contractual Products through other distribution intermediaries.

  
 § 4 Obligations of Inamed 

 

	 	(1)	Inamed shall preserve the confidentiality of the business and trade secrets of HemoSense, including after expiry of this Agreement. Inamed shall also oblige their employees
accordingly. 

  

	 	(2)	Inamed shall inform HemoSense about the market situation in the Contractual Territory and, upon learning of legal changes or of changes in requirements for official approval, about
customers’ requests, the popularity of the Contractual Products, the 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 2 of 12

 activities of competitors which are important for the business success of the Contractual Products in the
Contractual Territory. The reports to be submitted by Inamed shall not contain any information about the names and addresses of customers; HemoSense is not interested in the single customer relationships of Inamed. HemoSense is entitled to regularly
inspect Inamed’s business premises for quality control purposes (ISO 9001/9002) upon prior timely agreement of the date; HemoSense is not entitled to inspect Inamed’s business records. 
  

	 	(3)	Inamed is aware that the Contractual Products are medical devices that are governed by special legislation. This applies in particular to the system of reporting injuries to
patients which is regulated by the law. Inamed agrees to comply with this legislation, too, and to notify the competent bodies of any occurrences without delay. 

  

	 	(4)	Inamed shall immediately inform HemoSense of all actual and suspected violations of fair competition and all actual and suspected infringements of labeling and name rights,
intellectual property rights, copyrights and related rights by third parties of which they become aware and which affect HemoSense or the Contractual products. Inamed shall use their best efforts to support HemoSense in defending itself against such
infringements. 

  

	 	(5)	Inamed shall instruct their customers in the proper use and maintenance of the Contractual Products. 

  

	 	(6)	Inamed shall be obliged to distribute the Contractual Products under the trademarks and packed and presented as specific by HemoSense. 

  

	 	(7)	Inamed shall provide regular training courses for their staff during the life of this Agreement. 

  
 § 5 Obligations of HemoSense 
  

	 	(1)	HemoSense is obliged to take into reasonable consideration the interests of Inamed and support Inamed in their activities. 

  

	 	(2)	HemoSense must provide Inamed with the information and documents required for its distribution activities, such as instruction materials and brochures, free of charge. All documents
- to the extent not provided to customers or the training centers in the ordinary course of Inamed’s business - shall remain the property of HemoSense. 

  

	 	(3)	At the beginning of the Agreement HemoSense shall offer two training sessions for the Contractual Products, which Inamed should attend. 

  

	 	(4)	HemoSense shall ensure that the distribution of the Contractual Products in the Contractual Territory accordance with the provisions of this Agreement does not lead to the violation
of any statutes or regulations and, in particular, that any official permits, designations and approvals needed have been issued by the health insurance funds (Krankenkassen). 

  

	 	(5)	HemoSense shall keep confidential the business and trade secrets of Inamed and oblige its employees accordingly; this obligation shall survice the termination of this Agreement.

  
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 3 of 12

	 	(6)	HemoSense shall take measures to guarantee Inamed sufficient supplies of strips for patients using the INRatio Kit for a period of [***] - particularly in the event of insolvency.
[***] of these strips will be deposited in trust by HemoSense at the latter’s expense with a third party to be designated by HemoSense. Until further notice the trustee shall be the firm of I•Med•Pro GmbH. The strips will be deposited
for a period of [***] months from the date of delivery of the device concerned to Inamed. As the [***] pass, the number of strips deposited may be reduced pro rata; once the [***] period has expired there is no longer any need for any strips to be
deposited for the device concerned. On enquiry Inamed shall inform HemoSense without delay about the delivery dates of the devices and the residual periods. Inamed may only require the trustee to surrender the strips if and to the extent that it
needs them in order to be able to perform its own delivery obligations vis-à-vis customers and HemoSense is not in a position to supply the strips. HemoSense reserves the right to find equivalent solutions (e.g. replace the devices with other
makes available on the market). HemoSense shall inform Inamed without delay if it starts using a different trustee. 

  
 § 6 Minimum Purchase, Inventory, Sales Planning 
  

	 	(1)	Inamed plans to purchase and take delivery of the following quantities of Contractual Products from HemoSense: 

  

	 	a.	in the first year after signing of the Agreement and approval: [***] INRatio Kits and [***] Strips (boxes with 12 strips each) 

  

	 	b.	on conclusion of the Agreement: a starter pack with 10 INRatio Kits. 

  

	 	(2)	Inamed shall be obliged to set up and maintain at their own expense an inventory with a complete range of the Contractual Products. 

  

	 	(3)	Each month Inamed shall prepare a sales forecast for the next six months. 

  
 § 7 Prices and Terms of Payment 
  

	 	(1)	HemoSense shall sell the Contractual Products to Inamed at its end user list prices applicable at the time of entry into the respective sales contract, less a discount of a certain
amount. The end user list prices in force at the time of entry into this Agreement and the respective discounts are set forth in Attachment 1. 

  

	 	(2)	For each order of at least [***] INRatio Kits Inamed will receive a training set free of charge. 

  

	 	(3)	By granting the discount pursuant to the above, all claims of Inamed’s against HemoSense in connection with their activities to be performed under this Agreement shall be fully
settled. This does not apply to claims out of other agreements yet to be concluded (e.g. marketing agreements). 

  

	 	(4)	The following terms of payment shall apply to individual sales contracts which are concluded and performed between HemoSense and Inamed under this Agreement:

  

	 	a.	All HemoSense’s prices are exclusive of the applicable statutory value-added tax and apply ex warehouse of HemoSense’s European importer (currently I•Med•Pro
GmbH) and do not include forwarding costs, which shall be invoiced separately. Inamed will not be charged any forwarding costs if Contractual Products to a value of at least [***] after deduction of discounts are ordered. 

 

	 	b.	HemoSense’s invoices shall be due for payment within 30 days of delivery; [***] cash discount will be granted in case of payment within 14 calendar days of delivery. Payments
by Inamed shall not be deemed to have been made until HemoSense is able to dispose of the amount concerned. In the event 

  
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 4 of 12

 that Inamed is in default, HemoSense shall be entitled to demand default interests in the applicable
statutory amount. On provision of evidence, HemoSense can claim further damages for default. 
  

	 	c.	Inamed can only offset counterclaims that are res judicata or acknowledged by HemoSense and uncontested. 

  

	 	d.	Inamed can claim a right of retention only in respect of counterclaims that are based on the same contractual relationship and are uncontested or res judicata or about to
become res judicata. 

  

	 	e.	HemoSense will process the financial transactions through I•Med•Pro GmbH until further notice to Inamed. 

  

	 	(5)	Inamed are at liberty to set their prices and conditions in relation to their customers. 

  
 § 8 Order and Supply of Contractual Products 
  

	 	(1)	Within six weeks from the date hereof Inamed shall receive a training starter set free of charge for six training positions. 

  

	 	(2)	Until further notice by HemoSense, orders for Contractual Products shall be addressed to I•Med•Pro GmbH, Max-Planck-Str. 22, 50858 Cologne. 

  

	 	(3)	HemoSense/I•Med•Pro GmbH shall be entitled to reject Inamed’s orders only for justified cause. Justified cause shall exist in particular if, following notification in
accordance with § 2(3), HemoSense no longer markets the Contractual Product in question or cannot accept the order on account of production difficulties, production changeovers, failure of its suppliers to deliver, or unforeseeable events.

  

	 	(4)	HemoSense/I•Med•Pro GmbH shall inform Inamed without delay of any circumstances mentioned in subsection (3). 

  
 § 9 Warranty for Defects in Quality and Legal Defects 

 

	 	(1)	Unless otherwise provided below, Inamed’s rights in respect of defects in quality and legal defects (including delivery of the wrong products and short deliveries) shall be
governed by the relevant statutory provisions. 

  

	 	(2)	Where the Contractual Products delivered are faulty, HemoSense shall, after notification of the defect, perform the guarantee at its own expense by - at its option - repairing the
defect, delivering a defect-free Contractual Product or - in the case of legal defects - by procuring the rights of use necessary for use in conformity with the Agreement. Further claims by Inamed for defects are excluded. If a replacement is
delivered, Inamed shall return the faulty Contract Product. 

  

	 	(3)	Minor deviations from the agreed quality, and defects that do not materially affect the value or the fitness for use of the Contractual Products do not constitute grounds for the
assertion of claims for defects. 

  

	 	(4)	Inamed may only assert claims for defects if it has met its statutory obligations to inspect the goods and notify complaints in accordance with §§ 377, 381 German
Commercial Code. Obvious defects must be notified to HemoSense within one week of receipt of the respective Contractual Product; otherwise the assertion of claims for defects is excluded. The one-week time-period shall be deemed met if the letter of
notification is dispatched within that time. 

  

	 	(5)	The warranty period is two years from the date when Inamed deliver the Contract Product to their customer. Inamed agrees to inform HemoSense of the date of delivery without delay
and at any time upon request. 

  
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 5 of 12

	 	(6)	The burden of proof for all events leading to claims for defects, in particular for the defect itself, for the time of discovery of the defect and for the timeliness of the
complaint, shall rest with Inamed. 

  

	 	(7)	Save in the cases stipulated by law, the statutory assumption that a defect was already present when the risk passed to Inamed shall not apply, not even where a period of more than
six months lapses between the risk passing to Inamed and subsequently to Inamed’s customer. 

  

	 	(8)	Should HemoSense [***] if no INRatio devices are available to satisfy warranty claims, HemoSense shall [***] 

  
 § 10 Reservation of Title 
  

	 	(1)	The supplied Contract Products shall remain HemoSense’s property until such time as all HemoSense’s claims against Inamed out of the business relationship are settled.

  

	 	(2)	Inamed may only sell the Contract Products subject to reservation of title (“reserved Contract Products”) within the normal course of business. Inamed shall not be
entitled to pledge the reserved Contract products, assign them by way of security, or otherwise dispose of them in a manner that affects HemoSense’s title. Inamed hereby assigns its claims out of the resale of reserved Contract Products to
HemoSense and HemoSense accepts the assignment. Inamed is revocable authorised to collect the assigned claims as fiduciary for HemoSense. HemoSense may recall this authorization and the right to resell the reserved Contract Products if and as long
as Inamed defaults on a payment obligation vis-à-vis HemoSense. 

  

	 	(3)	Inamed agrees to treat the reserved Contract Products with due care for the duration of the reservation of title. 

  

	 	(4)	If Inamed defaults on payment of sums owing to HemoSense, then HemoSense may - without prejudice to its other rights - take back the reserved Contract Products and - after timely
prior announcement - realize them in some other manner as settlement for due claims against Inamedun. In this case Inamed shall grant HemoSense or HemoSense’s authorized representatives immediate access to the reserved Contract Products and
surrender them. 

  

	 	(5)	If requested to do so in writing by HemoSense, Inamed shall be obligated to take out appropriate insurance to cover the reserved Contract Products and to present HemoSense with
evidence of such insurance cover on request. Inamed hereby assign to HemoSense their claims under the insurance policy and HemoSense accepts the assignment. 

  
 §11 Limitation of Liability 
  

	 	(1)	Unless otherwise provided below, HemoSense shall be liable for damage sustained by Inamed only where it was caused by deliberate intent or gross negligence on the part of HemoSense.
This limitation of liability shall apply to all claims for damages and reimbursement of expenses - regardless of their cause in law - in particular to liability for positive violation of contractual duty and culpa in contrahendo. However, in case of
the breach of material contractual obligations involving slight negligence, HemoSense’s liability shall be limited to the amount of its sales price. On no account - save for deliberate intent or where a guarantee has been given - shall
HemoSense be liable for lost profit of Inamed. 

  
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 6 of 12

	 	(2)	Claims under the Product Liability Act and other mandatory statutory liability provisions, if any - where these provide for compulsory liability of HemoSense - are excluded from the
above limitation of liability. The limitation of liability under subsection (1), above, does not cover damage resulting from the absence of warranted characteristics, if any, or consequential damage against which HemoSense’s warranty was
intended to protect Inamed; HemoSense shall be liable for consequential damage only to the limited extent set forth in subsection (1). 

  
 § 12 Product Liability 
  

	 	(1)	Inamed shall neither alter the delivered Contract Products nor their design or packaging; in particular they shall not alter or remove warnings about the risks of improper use of
the Contract Products. If Inamed are in breach of the above, they shall indemnify HemoSense, for the purposes of their internal relationship, against product liability claims of third parties to the extent they are liable for the defect that
triggers liability. 

  

	 	(2)	If HemoSense is prompted to recall a Contractual Product due to a product defect, Inamed shall support HemoSense and undertake all reasonable measures requested by HemoSense. The
costs Inamed incurs for recalls shall be borne by HemoSense. 

  

	 	(3)	Inamed shall immediately inform HemoSense about any risks which may occur during the use of the Contractual Products and any product defects of which they may become aware.

  
 § 13 Term 
  

	 	(1)	The Agreement shall be concluded for an indefinite period of time. Both parties shall be entitled to terminate the Agreement on six months’ notice to the end of a calendar
month. 

  

	 	(2)	The Agreement may be terminated for good cause with immediate effect by either party. Good cause shall exist if circumstances arise which, considering the spirit and purpose of the
Agreement, make a continuation of the contractual relationship unreasonable for one or both parties. 

  

	 	(3)	The Agreement may be terminated for good cause with immediate effect by either party if 

  

	 	a.	the other party stops payments; 

  

	 	b.	debt settlement (bankruptcy, composition, insolvency) proceedings are instituted against the assets of the other party or an application is filed in this respect and, despite
specific request, the other party cannot prove the obvious unfoundedness of such application within a period of two weeks from receipt of the request; 

  

	 	c.	the other party grossly and permanently breaches its obligations to a considerable extent notwithstanding a warning letter. 

  

	 	(4)	HemoSense may terminate for good cause in particular if ownership of Inamed changes to the extent that a competitor of HemoSense’s acquires a shareholding in Inamed.

  

	 	(5)	Inamed may terminate for good cause in particular if 

  

	 	a.	HemoSense repeatedly and arbitrarily refuses orders made by Inamed without justified cause; or 

  

	 	b.	the distribution of the Contractual Products becomes unfeasible for Inamed in an economically practical way. 

  

	 	(6)	The notice of termination must be in writing. Electronic form is not acceptable. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 7 of 12

 § 14 Consequences of Termination 
  

	 	(1)	Termination and expiry of the Agreement as such shall not affect the individual sales contracts concluded between HemoSense and Inamed hereunder. Unsettled claims out of these
individual sales contracts shall be settled in accordance herewith. 

  
 After due notice in accordance with § 13(1) HemoSense is only obliged to accept orders from Inamed to the extent that Inamed can sell the respective Contractual products in the time period up to the termination
of the Agreement within the ordinary course of their business and does not have a sufficient stock of such products. HemoSense may request payment in advance for orders placed after receipt of due notice of termination. 
  

	 	(2)	Upon expiry of the Agreement Inamed shall return to HemoSense all documents made available to them pursuant to § 5(2). 

  

	 	(3)	Upon expiry of the Agreement Inamed must stop using the trademarks and signs of HemoSense’s, save where this is necessary to perform claims out of individual sales contracts in
accordance with § 14(1) hereof. Inamed shall discontinue calling themselves HemoSense’s “dealer” upon expiry of the Agreement. 

  

	 	(4)	Upon expiry of the Agreement Inamed shall be entitled to require HemoSense to take back all or part of the Contractual Products purchased by them from HemoSense in the ordinary
course of business, to the extent they are unused, undamaged and in their original packaging. Where HemoSense is not responsible for the termination of the Agreement, the purchase price payable for the returned Contractual Products shall be original
price less a flat rate of 5%. Inamed shall assert their take-back claim within a period of two months from the expiry of the Agreement. The costs and the risk of the redelivery shall be borne by Inamed if the Contractual Products are repurchased at
their request. Where HemoSense is responsible for the termination of the Agreement, it shall bear the cost of taking back the Contractural Products and the risk of the redelivery. 

  

	 	(5)	Upon expiry of the Agreement HemoSense shall be entitled to require Inamed to return all or some of their stock of Contractual Products purchased from HemoSense against payment of
the original purchase price less a flat rate of 3%, to the extent Inamed have not effected any subsequent sales with regard to these products and do not need them for the purpose of fulfilling their warranty obligations. HemoSense shall assert their
take-back claim within a period of two months from the expiry of the Agreement. The costs and the risk of the redelivery shall be borne by HemoSense if the Contractual Products are taken back at their request. 

  
 § 15 Final Provisions 
  

	 	(1)	Communications and correspondence for HemoSense relating to matters concerning this Agreement, including orders and complaints, shall be sent, until further notice by HemoSense, to
the following address: I•Med•Pro GmbH, Max-Planck-Str. 22, 50858 Cologne. Notices of termination shall also be sent directly to HemoSense. 

  

	 	(2)	The Agreement - including the attachments - contains all agreements between the parties relating to the subject matter hereof. 

  

	 	(3)	All amendments and additions to the Agreement must be in writing. The same shall apply to an amendment of this written-form requirement. Electronic form is not acceptable.

  

	 	(4)	Should one or more provisions of this Agreement be or become completely or partly invalid or unenforceable or should there be an omission herein, the validity of the remaining
provisions shall not be affected thereby. In place of the invalid or unenforceable provision, that valid and enforceable provision shall be deemed agreed which comes closest to the intended purpose. In the event of an omission, that provision shall
be deemed agreed which, considering the spirit and purpose of this Agreement, would have been agreed, had the parties considered the matter at the outset. 

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 8 of 12

	 	(5)	The venue and place of fulfillment for both parties shall be Berlin. 

  

	 	(6)	The Agreement and the purchase contracts concluded in performance hereof shall be governed by the law of the Federal Republic of Germany, with the exception of the UN Convention on
Contracts for the International Sale of Goods. 

  
 Attachments 1 - 3

  

			
	Berlin, April 7, 2003	 	Berlin, April 7, 2003
		
	 /s/ J.D. Merselis

	 	 /s/ I. Battke

	(HemoSense)	 	(Inamed)

  
 Supplement: 
  
 The parties agree that a marketing agreement is to be concluded within two months of being
listed with the health insurance funds as a remedy eligible for reimbursement. The main points shall be based on Ms. Hartwig’s presentation of the marketing concept on November 4, 2002 with a cost framework of € 30,000 not counting value
added tax, for the establishment of 15 additional training centers 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 9 of 12

 Attachment 1 
  
 Hemosense Product Price List:  
  

			
	 INRatio Kit:
	 	 
		
	 •      INRatio Meter
	 	 
		
	 •      Bag
	 	 
		
	 •      Box with 12 strips
	 	 
		
	 •      Pricker
	 	 
		
	 •      Lancets
	 	 
		
	 •      Instructions for use
	 	 
		
	 •      Short-form instructions for use
	 	 
		
	 •      Patient’s ID
	 	 
		
	 •      4 batteries
	 	 
		
	 •      Guarantee card
	 	List price: [***] discount [***]

  
 Strips: 
  

			
	12 strips per box	 	List price: [***] + VAT; discount [***]

  

						
	 	  	 Price list, 1.4.2003
 In Euro

	  	 Discount for
 Inamed

	Individual Products:	  	 	 	  	 
			
	 INRatio Meter
	  	 	[***]	  	[***]
	 Bag
	  	 	[***]	  	[***]
	 Pricker
	  	 	[***]	  	[***]
	 Instructions for use
	  	 	[***]	  	[***]
	 Short-form instructions for use
	  	 	[***]	  	[***]
	 Patient ID /100 pcs.
	  	 	[***]	  	[***]
	 Training manual
	  	 	[***]	  	[***]
	 Train the trainer instructions
	  	 	[***]	  	[***]
	 Set of transparencies
	  	 	[***]	  	[***]
	 Power supply unit
	  	 	[***]	  	[***]
	 Repair exchange
	  	 	[***]	  	[***]
	 Lancets
	  	 	 	  	[***]
			
	 Training Starter Pack 
	  	 	 	  	 
			
	 •      2 INRatio Kits
	  	 	 	  	 
	 •      Train the trainer manual
	  	 	 	  	 
	 •      10 sets of training instructions
	  	 	 	  	 
	 •      2 extra boxes of strips
	  	 	 	  	 
	 •      2 extra boxes with lancets
	  	 	 	  	 
	 •      10 patient IDs
	  	€	[***]	  	[***]
			
	 Training Pack
	  	 	 	  	 
			
	 •      2 boxes of strips
	  	 	 	  	 
			
	 •      5 sets of training instructions
	  	 	 	  	 
			
	 •      5 patient IDs
	  	 	 	  	 
			
	 •      Lancets for 5 patients
	  	€	[***]	  	[***]

  
 All prices are exclusive of VAT at the
time of delivery. 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 10 of 12

 Attachment 2 
  
 Contractual Territory: 
  
 Berlin 
 Brandenburg 
 Mecklenburg-Vorpommern 
 Saxony 
 Saxony-Anhalt

  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 11 of 12

 Attachment 3  
  
 Power of Attorney for Representative appointed by HemoSense under § 1 (5) of the Agreement 
  
 The power of attorney for the representative appointed by HemoSense under § 1 (5) of the
Agreement (initially I•Med•Pro GmbH) extends solely to the following acts and declarations: 
  

	1.	Importing the Contractual Products 

  

	2.	VAT processing for the Contractual Products 

  

	3.	Accepting orders from Inamed on the terms and outline conditions set forth in the Agreement, and making the deliveries accordingly 

  

	4.	Giving instructions on the use of the Contract Products 

  

	5.	Producing and delivering brochures and training materials for the Contractual Products 

  

	6.	Issuing invoices for the delivered Contractual Products on behalf of HemoSense 

  

	7.	Collecting payments 

  

	8.	Forwaring payments to HemoSense or a third party designated by HemoSense 

  

	9.	Receiving notification of product defects within the meaning of the Medicinal Device Act and the Product Liability Act; receiving complaints 

  

	10.	Delivering replacements for faulty devices and/or strips under guarantee 

  

	11.	Keeping and delivering strips, as trustee, under § 5(6) of the Agreement 

  

HemoSense may appoint a new representative at any time, dismiss the present one without appointing a new one, and limit the nature and scope of its duties and powers
or cancel the same at any time by declaration in written, electronic or verbal form. The further reciprocal rights and obligations of the representative and HemoSense are regulated in the agreements entered into between them. 
  

	***	 	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

	
	Page 12 of 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]